Denver ASH Review Orange Logo

Presenters

2023

Ajay Major, MD, MBA

Updates on Lymphoma

Gemyln George, MD

UPDATES ON HEMOGLOBINOPATHIES / SICKLE CELL​

Dan Sherbenou, MD, PhD

Updates on myeloma

Maria Amaya, MD, PhD

Updates on AML / MDS

Jenna Moyer, MD

Updates on Thrombosis / Bleeding

Terry Fry, MD

Cellular Therapies

Learning Objectives

By the end of the review, attendees will be better equipped to:


  • Determine which patients with hematologic malignancy may benefit from specific targeted therapy

  • Recognize myriad of presentations of patients with hematologic illnesses

  • Identify higher-risk patients with hematologic malignancy and determine the best available therapies

  • Prescribe individualized plans for patients with hematologic malignancies based on specific disease characteristics (genetics, molecular markers, etc.)

  • Manage complications of hematologic malignancies in an outpatient setting

  • Familiarize health care practitioners with the latest updates as per clinical trial data in the proper diagnosis and treatment of benign hematologic diseases, such as sickle cell anemia, coagulopathies, and autoimmune hemolytic anemias

Continuing Education Credit

CONTINUING MEDICAL EDUCATION

 

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in this activity.



CONTINUING NURSING EDUCATION


More information regarding CNE credit coming soon.

2022

Steve Bair, MD

Lymphomas

Brady Stein, MD

Myeloproliferative Neoplasms

Peter Forsberg, MD

Multiple Myeloma

Christine McMahon, MD

MDS / AML

Ara Metjian, MD

Benign Hematology

Clay Smith, MD

Innovations